Pro-apoptotic TP53 homolog TAp63 is repressed via epigenetic silencing and B-cell receptor signalling in chronic lymphocytic leukaemia

Leigh A. Humphries, J. Claire Godbersen, Olga V. Danilova, Prabhjot Kaur, Brock C. Christensen, Alexey Danilov

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Chronic lymphocytic leukaemia (CLL) is an accumulative disorder marked by deficient apoptosis. The TP53 homolog TAp63 promotes apoptosis and chemosensitivity in solid tumours and its deregulation may contribute to CLL cell survival. We found that TAp63α was the most prevalent TP63 isoform in CLL. Compared to healthy B cells, TAp63 mRNA was repressed in 55·7% of CLL samples. TP63 promoter methylation was high in CLL and inversely correlated with TP63 protein expression in B-cell lymphoma cell lines. siRNA-mediated knockdown of TP63 resulted in partial protection from spontaneous apoptosis accompanied by reductions in PMAIP1 (NOXA), BBC3 (PUMA), and BAX mRNA in CLL cells and increased proliferation of Raji lymphoma cells. TAp63 mRNA levels were higher in CLL with unmutated IGHV. B-cell receptor (BCR) engagement led to repression of TP63 mRNA expression in malignant B cells, while pharmacological inhibition of BCR signalling prevented TP63 downregulation. MIR21, known to target TAp63, correlated inversely with TAp63 expression in CLL, and BCR-mediated downregulation of TP63 was accompanied by MIR21 upregulation in most CLL samples. Our data illustrate the pro-apoptotic function of TP63, provide insights into the mechanisms of BCR-targeting agents, and establish a rationale for designing novel approaches to induce TP63 in CLL and B-cell lymphoma.

Original languageEnglish (US)
Pages (from-to)590-602
Number of pages13
JournalBritish Journal of Haematology
Volume163
Issue number5
DOIs
StatePublished - Dec 2013
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Epigenomics
B-Lymphocytes
Messenger RNA
B-Cell Lymphoma
Apoptosis
Down-Regulation
Methylation
Small Interfering RNA
Lymphoma
Cell Survival
Protein Isoforms
Up-Regulation
Cell Proliferation
Pharmacology
Cell Line

Keywords

  • B-cell receptor
  • Chronic lymphocytic leukaemia
  • Methylation
  • TP63

ASJC Scopus subject areas

  • Hematology

Cite this

Pro-apoptotic TP53 homolog TAp63 is repressed via epigenetic silencing and B-cell receptor signalling in chronic lymphocytic leukaemia. / Humphries, Leigh A.; Godbersen, J. Claire; Danilova, Olga V.; Kaur, Prabhjot; Christensen, Brock C.; Danilov, Alexey.

In: British Journal of Haematology, Vol. 163, No. 5, 12.2013, p. 590-602.

Research output: Contribution to journalArticle

Humphries, Leigh A. ; Godbersen, J. Claire ; Danilova, Olga V. ; Kaur, Prabhjot ; Christensen, Brock C. ; Danilov, Alexey. / Pro-apoptotic TP53 homolog TAp63 is repressed via epigenetic silencing and B-cell receptor signalling in chronic lymphocytic leukaemia. In: British Journal of Haematology. 2013 ; Vol. 163, No. 5. pp. 590-602.
@article{819273afd5c4465c9f777dbd557d61c7,
title = "Pro-apoptotic TP53 homolog TAp63 is repressed via epigenetic silencing and B-cell receptor signalling in chronic lymphocytic leukaemia",
abstract = "Chronic lymphocytic leukaemia (CLL) is an accumulative disorder marked by deficient apoptosis. The TP53 homolog TAp63 promotes apoptosis and chemosensitivity in solid tumours and its deregulation may contribute to CLL cell survival. We found that TAp63α was the most prevalent TP63 isoform in CLL. Compared to healthy B cells, TAp63 mRNA was repressed in 55·7{\%} of CLL samples. TP63 promoter methylation was high in CLL and inversely correlated with TP63 protein expression in B-cell lymphoma cell lines. siRNA-mediated knockdown of TP63 resulted in partial protection from spontaneous apoptosis accompanied by reductions in PMAIP1 (NOXA), BBC3 (PUMA), and BAX mRNA in CLL cells and increased proliferation of Raji lymphoma cells. TAp63 mRNA levels were higher in CLL with unmutated IGHV. B-cell receptor (BCR) engagement led to repression of TP63 mRNA expression in malignant B cells, while pharmacological inhibition of BCR signalling prevented TP63 downregulation. MIR21, known to target TAp63, correlated inversely with TAp63 expression in CLL, and BCR-mediated downregulation of TP63 was accompanied by MIR21 upregulation in most CLL samples. Our data illustrate the pro-apoptotic function of TP63, provide insights into the mechanisms of BCR-targeting agents, and establish a rationale for designing novel approaches to induce TP63 in CLL and B-cell lymphoma.",
keywords = "B-cell receptor, Chronic lymphocytic leukaemia, Methylation, TP63",
author = "Humphries, {Leigh A.} and Godbersen, {J. Claire} and Danilova, {Olga V.} and Prabhjot Kaur and Christensen, {Brock C.} and Alexey Danilov",
year = "2013",
month = "12",
doi = "10.1111/bjh.12580",
language = "English (US)",
volume = "163",
pages = "590--602",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Pro-apoptotic TP53 homolog TAp63 is repressed via epigenetic silencing and B-cell receptor signalling in chronic lymphocytic leukaemia

AU - Humphries, Leigh A.

AU - Godbersen, J. Claire

AU - Danilova, Olga V.

AU - Kaur, Prabhjot

AU - Christensen, Brock C.

AU - Danilov, Alexey

PY - 2013/12

Y1 - 2013/12

N2 - Chronic lymphocytic leukaemia (CLL) is an accumulative disorder marked by deficient apoptosis. The TP53 homolog TAp63 promotes apoptosis and chemosensitivity in solid tumours and its deregulation may contribute to CLL cell survival. We found that TAp63α was the most prevalent TP63 isoform in CLL. Compared to healthy B cells, TAp63 mRNA was repressed in 55·7% of CLL samples. TP63 promoter methylation was high in CLL and inversely correlated with TP63 protein expression in B-cell lymphoma cell lines. siRNA-mediated knockdown of TP63 resulted in partial protection from spontaneous apoptosis accompanied by reductions in PMAIP1 (NOXA), BBC3 (PUMA), and BAX mRNA in CLL cells and increased proliferation of Raji lymphoma cells. TAp63 mRNA levels were higher in CLL with unmutated IGHV. B-cell receptor (BCR) engagement led to repression of TP63 mRNA expression in malignant B cells, while pharmacological inhibition of BCR signalling prevented TP63 downregulation. MIR21, known to target TAp63, correlated inversely with TAp63 expression in CLL, and BCR-mediated downregulation of TP63 was accompanied by MIR21 upregulation in most CLL samples. Our data illustrate the pro-apoptotic function of TP63, provide insights into the mechanisms of BCR-targeting agents, and establish a rationale for designing novel approaches to induce TP63 in CLL and B-cell lymphoma.

AB - Chronic lymphocytic leukaemia (CLL) is an accumulative disorder marked by deficient apoptosis. The TP53 homolog TAp63 promotes apoptosis and chemosensitivity in solid tumours and its deregulation may contribute to CLL cell survival. We found that TAp63α was the most prevalent TP63 isoform in CLL. Compared to healthy B cells, TAp63 mRNA was repressed in 55·7% of CLL samples. TP63 promoter methylation was high in CLL and inversely correlated with TP63 protein expression in B-cell lymphoma cell lines. siRNA-mediated knockdown of TP63 resulted in partial protection from spontaneous apoptosis accompanied by reductions in PMAIP1 (NOXA), BBC3 (PUMA), and BAX mRNA in CLL cells and increased proliferation of Raji lymphoma cells. TAp63 mRNA levels were higher in CLL with unmutated IGHV. B-cell receptor (BCR) engagement led to repression of TP63 mRNA expression in malignant B cells, while pharmacological inhibition of BCR signalling prevented TP63 downregulation. MIR21, known to target TAp63, correlated inversely with TAp63 expression in CLL, and BCR-mediated downregulation of TP63 was accompanied by MIR21 upregulation in most CLL samples. Our data illustrate the pro-apoptotic function of TP63, provide insights into the mechanisms of BCR-targeting agents, and establish a rationale for designing novel approaches to induce TP63 in CLL and B-cell lymphoma.

KW - B-cell receptor

KW - Chronic lymphocytic leukaemia

KW - Methylation

KW - TP63

UR - http://www.scopus.com/inward/record.url?scp=84887611978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887611978&partnerID=8YFLogxK

U2 - 10.1111/bjh.12580

DO - 10.1111/bjh.12580

M3 - Article

C2 - 24117128

AN - SCOPUS:84887611978

VL - 163

SP - 590

EP - 602

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -